drugset / Trial / NCT07142291
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Timeline
- Start
- 2025-11-25
- Primary completion
- 2027-03
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cromolyn | Small molecule | 17.1 mg | Inhaled |
| Subject | Cromolyn | Small molecule | 34.2 mg | Inhaled |
| Background | Riluzole | Small molecule | 50 mg | Oral |